Dataset from A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00011925
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC and with non-FLC solid tumors and to assess the T-cell response.
创建时间：
2026-04-09
